——————————————————————————– Jesper Brandgaard, Novo Nordisk A/S – EVP and CFO  ——————————————————————————– So to elaborate on the M&A, you said the word of turning around the business. I think we have a quite strong portfolio of products we are rolling out, so we have a quite [limitless] pipeline. Also, the US is doing very well. In the US we have a lower price point but still we expect that we can take volume. So, I still think we have a strong organic business. So in that context, bolt-on acquisitions are more realistic than last conforming (inaudible). have a peek at this web-siteSo I think that’s — we are on to that. ——————————————————————————– Mads Krogsgaard Thomsen, Novo Nordisk A/S – EVP, Chief Science Officer  ——————————————————————————– And I think in reality you are seeing a gradual diversification of our business towards having a bigger dependence on emerging markets to provide the growth, but that’s also where we see the volume growth in patient numbers. And we have the best portfolio in insulin, we have the best portfolio of GLP-1. It makes sense for us to focus our strategy on diabetes care.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/edited-transcript-novo-b-co-234328675.html